How many stocks are there of MannKind?
The current number of stocks of MannKind is 267.01 M undefined.
MannKind Stocks 2024
MannKind Stocks
267.01 M
Ticker
MNKD
ISIN
US56400P7069
WKN
A2DMZL
In 2024, MannKind had 267.01 M outstanding stocks, a 0% change from the 267.01 M stocks in the previous year.
The MannKind Stocks history
| YEAR | NUMBER OF STOCKS (undefined USD) |
|---|---|
| 2029e | 267.01 |
| 2028e | 267.01 |
| 2027e | 267.01 |
| 2026e | 267.01 |
| 2025e | 267.01 |
| 2024e | 267.01 |
| 2023 | 267.01 |
| 2022 | 257.1 |
| 2021 | 249.2 |
| 2020 | 222.6 |
| 2019 | 195.6 |
| 2018 | 144.1 |
| 2017 | 104.2 |
| 2016 | 92.1 |
| 2015 | 81.2 |
| 2014 | 77 |
| 2013 | 59.9 |
| 2012 | 36.2 |
| 2011 | 24.4 |
| 2010 | 22.7 |
| 2009 | 21.3 |
| 2008 | 20.3 |
| 2007 | 16 |
| 2006 | 10.2 |
| 2005 | 8 |
| 2004 | 5 |
MannKind shares outstanding US56400P7069 · A2DMZL
The number of shares was MannKind in 2023 — This indicates how many shares 267.014 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.
3 years
5 years
10 years
25 Years
Max
Number of stocks
Details
Revenue, EBIT and Earnings per share
ⓘRevenue Per Share
Revenue per share represents the total revenue MannKind earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.
EBIT Per Share
EBIT per share indicates MannKind's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.
Income Per Share
Income per share, or earnings per share (EPS), reveals the portion of MannKind’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.
Expected Values
Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating MannKind's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.
| Number of stocks | |
|---|---|
| 2004 | 5 M Aktien |
| 2005 | 8 M Aktien |
| 2006 | 10.2 M Aktien |
| 2007 | 16 M Aktien |
| 2008 | 20.3 M Aktien |
| 2009 | 21.3 M Aktien |
| 2010 | 22.7 M Aktien |
| 2011 | 24.4 M Aktien |
| 2012 | 36.2 M Aktien |
| 2013 | 59.9 M Aktien |
| 2014 | 77 M Aktien |
| 2015 | 81.2 M Aktien |
| 2016 | 92.1 M Aktien |
| 2017 | 104.2 M Aktien |
| 2018 | 144.1 M Aktien |
| 2019 | 195.6 M Aktien |
| 2020 | 222.6 M Aktien |
| 2021 | 249.2 M Aktien |
| 2022 | 257.1 M Aktien |
| 2023 | 267.01 M Aktien |
| 2024e | 267.01 M Aktien |
| 2025e | 267.01 M Aktien |
| 2026e | 267.01 M Aktien |
| 2027e | 267.01 M Aktien |
| 2028e | 267.01 M Aktien |
| 2029e | 267.01 M Aktien |
MannKind Aktienanalyse
What does MannKind do?
MannKind Corp is a biopharmaceutical company that specializes in the development, production, and marketing of inhalable medications. The company was founded in 1991 by renowned scientist Alfred E. Mann and is headquartered in Westlake Village, California. MannKind Corp's history began with its founding in 1991 and the development of technologies for manufacturing injectable drugs. Over the years, the company has continuously evolved its technologies and now specializes in inhalable medications. MannKind Corp offers a wide portfolio of products in various areas, with the main areas being diabetes, lung and respiratory diseases, and cancer and immunology. The company develops and produces innovative medications and inhalation devices that allow patients to fight their illnesses. In particular, MannKind Corp has achieved significant success in the field of diabetes treatment. The company has developed an inhalable insulin solution that allows patients to quickly and easily inhale insulin. This novel insulin preparation called Afrezza was launched in the U.S. market in 2015 and greatly improves the treatment of both Type 1 and Type 2 diabetes. With Afrezza, MannKind Corp has achieved a milestone in medical history. In addition to Afrezza, MannKind is also working on other promising projects such as an inhalable drug for COPD (chronic obstructive pulmonary disease), an inhalable painkiller, and a cancer medication. The company also operates its own research department to develop new drugs and therapies. To realize its business model, the company utilizes partnerships and joint ventures to successfully bring its products to market. For example, it has formed a partnership with Sanofi, a globally leading biopharmaceutical company, to launch Afrezza in Europe. It has also established a partnership with Receptor Life Sciences Inc. in the U.S. to develop an inhalable cannabinoid medication for neuropathic pain. MannKind Corp is a company with ambitious goals and visions. It has already made significant advancements in development and elevated the treatment of diseases to a higher level. With its innovative products and technologies, the company remains a leading player in the biopharmaceutical industry and contributes to improving people's lives. MannKind ist eines der beliebtesten Unternehmen auf Eulerpool.com.Stocks Details
Evaluating MannKind's Shares Outstanding
MannKind's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.
Year-to-Year Comparison
Tracking the changes in MannKind’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.
Impact on Investments
For investors, understanding MannKind’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.
Interpreting Changes in Shares Outstanding
Variances in MannKind’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.
Frequently Asked Questions about MannKind stock
What does Number of Shares / OutstandingShares mean?
The outstanding shares (or issued shares) of MannKind are the total number of shares issued and actively held by shareholders - both external investors and company insiders. However, these must be actual shares. may grant stock options to executives that can be converted into shares.
How has the number of shares of MannKind evolved in recent years?
The number of shares of MannKind has increased by 0% gestiegen compared to last year.
What does the number of shares mean for investors?
The number of shares outstanding is used to calculate key metrics such as a company's market capitalization, earnings per share (EPS), and cash flow per share (CFPS). The number of outstanding shares of a company is not static and can fluctuate greatly over time.
Why does the number of stocks fluctuate?
There are various factors that can lead to a change. MannKind as a company can issue new shares, carry out stock splits or reverse splits.
Does the number of shares have an impact on the performance of MannKind?
There is no tangible long-term evidence or study that stocks with a certain number of shares (regardless of Mega/Large/Mid/Small Cap) would yield significantly higher returns than others. There are occasional small studies (limited number of stocks, short investment period) that certain classes outperform or have higher risk, but none of them are 1. conclusive (cause-effect is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).
How much dividend does MannKind pay?
Over the past 12 months, MannKind paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, MannKind is expected to pay a dividend of 0 USD.
What is the dividend yield of MannKind?
The current dividend yield of MannKind is .
When does MannKind pay dividends?
MannKind pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of MannKind?
MannKind paid dividends every year for the past 0 years.
What is the dividend of MannKind?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is MannKind located?
MannKind is assigned to the 'Health' sector.
Wann musste ich die Aktien von MannKind kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of MannKind from 7/17/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 7/17/2024.
When did MannKind pay the last dividend?
The last dividend was paid out on 7/17/2024.
What was the dividend of MannKind in the year 2023?
In the year 2023, MannKind distributed 0 USD as dividends.
In which currency does MannKind pay out the dividend?
The dividends of MannKind are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
The MannKind stock can be added to a savings plan with the following providers: Trade Republic
Andere Kennzahlen von MannKind
Our stock analysis for MannKind Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of MannKind Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
